Pharmacokinetics and Tolerability of Duloxetine following Oral Administration to Healthy Chinese Subjects

被引：0
|
作者：
Si Tianmei
Mary Pat Knadler
Ming T. Lim
Kwee Poo Yeo
Leyan Teng
Shu Liang
Alan X. Pan
Evelyn D. Lobo
机构：
[1] Peking University Institute of Mental Health,Drug Disposition
[2] Eli Lilly and Company,Lilly
[3] Natlonal University of Singapore,NUS Centre for Clinical Pharmacology
[4] Global Pharmacokinetic/Pharmacodynamic/Trial Simulation,Eli Lilly and Company, Drug Disposition
来源：
Clinical Pharmacokinetics | 2007年 / 46卷
关键词：
Multiple Dose; Duloxetine; CYP1A2 Activity; Intermediate Metabolisers; Japanese Subject;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：767 / 775
页数：8
相关论文
共 50 条
  • [41] Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects
    Johnson, Theodore R.
    Goulet, Lance
    Smith, Evan B.
    Yamazaki, Shinji
    Walker, Gregory S.
    Tan, Weiwei
    Li, Chunze
    Ni, Yao
    Bedarida, Gabriella
    Brega, Nicoletta
    Dalvie, Deepak
    Smith, Bill J.
    DRUG METABOLISM REVIEWS, 2011, 43 : 77 - 77
  • [42] PHARMACOKINETICS OF PANTOPRAZOLE FOLLOWING SINGLE INTRAVENOUS AND ORAL-ADMINISTRATION TO HEALTHY MALE-SUBJECTS
    PUE, MA
    LAROCHE, J
    MEINEKE, I
    DEMEY, C
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 44 (06) : 575 - 578
  • [43] PHARMACOKINETICS OF DIAZEPAM FOLLOWING MULTIPLE-DOSE ORAL-ADMINISTRATION TO HEALTHY HUMAN SUBJECTS
    EATMAN, FB
    COLBURN, WA
    BOXENBAUM, HG
    POSMANTER, HN
    WEINFELD, RE
    RONFELD, R
    WEISSMAN, L
    MOORE, JD
    GIBALDI, M
    KAPLAN, SA
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1977, 5 (05): : 481 - 494
  • [44] Pharmacokinetics, Safety, and Tolerability of Letermovir Following Single- and Multiple-Dose Administration in Healthy Japanese Subjects
    Asari, Kazuhiko
    Ishii, Mikio
    Yoshitsugu, Hiroyuki
    Wakana, Akira
    Fancourt, Craig
    Yoon, Esther
    Furihata, Kenichi
    McCrea, Jacqueline B.
    Stoch, S. Aubrey
    Iwamoto, Marian
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (08): : 938 - 948
  • [45] Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects
    Lantz, RJ
    Gillespie, TA
    Rash, TJ
    Kuo, F
    Skinner, M
    Kuan, HY
    Knadler, MP
    DRUG METABOLISM AND DISPOSITION, 2003, 31 (09) : 1142 - 1150
  • [46] Pharmacokinetics and Tolerability of Minodronic Acid Tablets in Healthy Chinese Subjects and Food and Age Effects on the Pharmacokinetics
    Zhou, Ying
    He, Xiaomeng
    Li, Huqun
    Ni, Yang
    Xu, Mingzhen
    Sattar, Haseeb
    Chen, Hui
    Li, Weiyong
    CLINICAL THERAPEUTICS, 2015, 37 (04) : 869 - 876
  • [47] Assessing the pharmacokinetics and tolerability of single ascending doses of desvenlafaxine in healthy chinese subjects
    Nichols, A.
    Guan, L.
    Abell, M.
    Frick, G.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 205 - 205
  • [48] Pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Japanese, Chinese, and white subjects
    Aiudi, Anthony
    Miller, Benjamin
    Krishna, Gopal
    Adedoyin, Adedayo
    Xiao, Alan
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 (06) : 625 - 633
  • [49] SAFETY/TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ORAL DOSES OF APREMILAST IN HEALTHY MALE SUBJECTS
    Wu, A.
    Rohane, P.
    Ng, J.
    DeGroot, B.
    Colgan, B.
    Laskin, O. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S26 - S26
  • [50] Pharmacokinetics and Tolerability of Intramuscular, Oral and Intravenous Aripiprazole in Healthy Subjects and in Patients with Schizophrenia
    David W. Boulton
    Georgia Kollia
    Suresh Mallikaarjun
    Bernard Komoroski
    Anjali Sharma
    Lawrence J. Kovalick
    Richard A. Reeves
    Clinical Pharmacokinetics, 2008, 47 : 475 - 485
12345